<DOC>
	<DOCNO>NCT00976404</DOCNO>
	<brief_summary>The objective study discover new approach human immunodeficiency virus ( HIV ) eradicate infected individual intensified antiretroviral treatment couple immunomodulation . The hypothesis eradication possible potent antiretroviral drug deliver conjunction immunomodulatory agent simultaneously attack viral reservoir .</brief_summary>
	<brief_title>Therapeutic Intensification Plus Immunomodulation Decrease HIV-1 Viral Reservoir</brief_title>
	<detailed_description>The objective study measure impact immunomodulation plus treatment intensification HIV reservoir HIV-infected patient viral suppression combination antiretroviral therapy . Treatment regimens first intensified addition raltegravir maraviroc 8 week follow immunomodulation NIH HIV-rAd5 vaccine plus DNA prime-boost 24 week . The primary endpoint measurement change peripheral cellular HIV DNA . A decrease 0.5 log consider significant . A secondary endpoint include change HIV DNA rectal mucosa , immunologic change peripheral blood safety .</detailed_description>
	<mesh_term>HIV Infections</mesh_term>
	<mesh_term>Vaccines</mesh_term>
	<mesh_term>Maraviroc</mesh_term>
	<mesh_term>Raltegravir Potassium</mesh_term>
	<criteria>HIV1 infection At least 3 year ART without interruption ( less one month cumulative ) ART regimen unchanged 3 month prior screen One HIV plasma viral load ( RNA ) document least 3 year prior entry , least 2 HIV plasma viral load ( RNA ) document per year thereafter HIV plasma viral load ( RNA ) ≤ 500 copies/mL least 3 year prior entry , HIV plasma viral load &lt; 500 copies/mL &gt; 90 % measure thereafter HIV plasma viral load ( RNA ) limit detection value within past year ( one virologic blip allow ) HIV plasma viral load limit detection within 60 day entry CD4+ count ≥ 350 cells/mm3 within 60 day entry Proviral DNA ≥10 ≤1000 copies/106 PBMCs within 75 day entry Adeno5 neutralize antibody titer 250 less within 75 day entry Hemoglobin ≥ 10 g/dL within 60 day entry Platelets ≥ 100,000 per microliter within 60 day entry Hepatic transaminase ( ALT AST ) ≤ 2.5 x ULN within 60 day entry Creatinine clearance &gt; 50 mL/min CockcroftGault equation within 60 day entry Sexually active men woman practice least one form barrier birth control ( male partner use condom , female partner use condom , barrier contraception , etc ) Pregnancy Inability unwillingness provide inform consent HBsAg positive HCV antibody positive HCV RNA detectable Previous use integrase inhibitor ( ie raltegravir ) CCR5 inhibitor ( ie maraviroc , vicriviroc ) . Use raltegravir nontreatment failure indication intensification toxicity switch allow . Immunologic therapeutic intervention ( e.g . IL2 ) within past year Participation another clinical drug device trial last dose drug within past 30 day investigational medical device currently implant Diagnosis cancer within last 5 year ( except basal cell cutaneous cancer cutaneous KS require systemic therapy ) Comorbid condition expect survival less 12 month History hypersensitivity vaccination History autoimmune disease , systemic lupus erythematosis ( SLE ) Hashimoto 's thyroiditis Active drug alcohol use dependence , opinion site investigator , would interfere adherence study requirement</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>September 2014</verification_date>
	<keyword>HIV-1 infection</keyword>
	<keyword>Treatment intensification</keyword>
	<keyword>Immunomodulation</keyword>
	<keyword>HIV-rAd5 vaccine</keyword>
</DOC>